Alnylam Pharmaceuticals (Nasdaq: ALNY) announced it will present clinical and real-world data from its transthyretin-mediated amyloidosis (ATTR) and hypertension programs ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA